Merck aims for growth in China with Sinopharm

Big Pharma's new promised land has spawned yet another major enterprise. Merck (NYSE: MRK [1]) is negotiating a partnership with China's Sinopharm Group, aiming to sell its vaccines--and perhaps prescription drugs--in that vast-and-growing market.

The two companies say they're working on a deal to commercialize Merck's human papillomavirus shot and other "mutually selected" vaccines for the Chinese market. Drug sales could follow. Although Merck has its own operations in China--including some 3,000 sales reps, a 90 percent increase since 2007, Reuters reports--this is the drugmaker's first effort to partner with a domestic company.

Like other drugmakers that have found partners in China, Merck considers emerging markets a key part of its growth strategy. "Expanding our business in emerging markets throughout the world is critical to the mission and growth of Merck/MSD and innovative partnerships are a key element of our approach," CEO Richard Clark (photo [2]) says in a statement.

- get the release [3] from Merck
- see the Reuters news [4]

ALSO:  Merck paid claims to the families of 3,468 users of its Vioxx painkiller who died of heart attacks or strokes, a court-appointed administrator told a judge. Report [5]

Related Articles:
China's Sinopharm mulls deal for Nanjing Pharma [6]
Chinese healthcare spending up 50% [7]
Will new Chinese rules obstruct pharma trade? [8]
Are emerging markets enough to boost Big Pharma? [9]
The pharma trifecta: Generics, new markets, and personalization [10]